Clinical Trial Update: A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial evaluating docosahexaenoic acid (DHA) in metastatic breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Cancer Estrogen Receptor-positive
• Breast Cancer Progesterone Receptor-positive

Drugs mentioned

• Docosahexaenoic acid (docosahexaenoic acid)

Snippet

Sponsor: University Hospital, Tours | Conditions: Metastatic Breast Cancer, Progesterone Receptor Positive Tumor | Phase 3 | Status: TERMINATED